ASCO 2025: Dual-target CAR T-cell therapy slows growth of aggressive brain cancer
A dual-target CAR T cell therapy approach shows promise for slowing tumour growth in glioblastoma. Tumours became…
Browsing: Featured
ASCO 2025: Rusfertide shows promise for polycythemia vera treatment
Results from the Phase 3, randomised, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia…
ASCO 2025: Switch to camizestrant after liquid biopsy detection of breast cancer recurrence improves outcomes
A large prospective, randomised clinical trial in patients with advanced breast cancer has found that…
ASCO 2025: Exercise programme may lower risk of recurrence and death for some colon cancer survivors
New study results show that a structured exercise programme following surgery and adjuvant chemotherapy reduced…
ASCO 2025: Perioperative treatment with durvalumab and FLOT chemo can reduce risk of recurrence for some gastric cancers
Results from an international phase 3 clinical trial found that treating stage II, III, and…
ASCO 2025: Zanidatamab plus chemotherapy shows strong first-line efficacy in HER2-positive gastro-oesophageal adenocarcinoma
A phase 2 trial reports high response rates and durable outcomes in treatment-naive patients, presented…
Paediatric investigation study identifies immune drivers of medulloblastoma metastasis using explainable AI
Medulloblastoma, the most common malignant paediatric brain tumour, presents substantial clinical challenges due to its…
AI could help improve early detection of interval breast cancers
A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center suggests that…
GLP-1 receptor agonists show anti-cancer benefits beyond weight loss
New research presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14…
Cancer Council Victoria’s statewide Bowel Screening Campaign results
Analysis undertaken by the Daffodil Centre shows an additional 25,080 Victorians completed and returned a…